Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsRaw MaterialsReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Outlook Therapeutics (OTLK) Operating Leases (2019 - 2025)

Outlook Therapeutics (OTLK) has disclosed Operating Leases for 4 consecutive years, with $171988.0 as the latest value for Q4 2025.

  • On a quarterly basis, Operating Leases fell 26.22% to $171988.0 in Q4 2025 year-over-year; TTM through Dec 2025 was $171988.0, a 26.22% decrease, with the full-year FY2025 number at $188801.0, changed N/A from a year prior.
  • Operating Leases was $171988.0 for Q4 2025 at Outlook Therapeutics, down from $188801.0 in the prior quarter.
  • In the past five years, Operating Leases ranged from a high of $233113.0 in Q4 2024 to a low of $171988.0 in Q4 2025.